

Antibody	Fluorophore	Clone	RRID	Cat#	Company	Dilution (in FACS buffer)
CD3	PE-Cy7	SK7	AB_396896	557851	BD	1:100
CD4	APC-Cy7	SK3	AB_2868770	341115	BD	1:50
CD8	BV605	SK1	AB_2869551	564116	BD	1:100
PD-1 (CD279)	FITC	MIH4	AB_2159176	557860	BD	1:20
PD-L1 (CD274)	PE	MIH1	AB_647198	557924	BD	1:10
PD-L2 (CD273)	APC	MIH18	AB_647162	557926	BD	1:10

Supplemental Table 1. Antibodies used in FACS analysis. BD – Becton Dickinson.

Antibody	Clone	RRID	Cat#	Company	Dilution (in skimmed milk)
PD-1 (CD279)	D4W2J	AB_2728833	86163	Cell Signaling Technology	1:1000
PD-L1 (CD274)	E1L3N	AB_2687655	13684	Cell Signaling Technology	1:1000
PD-L2 (CD273)	D7U8C	AB_2799999	82723	Cell Signaling Technology	1:1000
IL-1β	D3U3E	AB_2737350	12703	Cell Signaling Technology	1:500
IL-6	D3K2N	AB_2687897	12153	Cell Signaling Technology	1:500
TGFβ2	n/a	n/a	ab167655	Abcam	1:1000
AXL	C89E7	AB_11217435	8661	Cell Signaling Technology	WB: 1:1000 ICC: 1:100
IDO1	D5J4E	AB_2636818	86630	Cell Signaling Technology	1:1000
Goat Anti-Rabbit IgG (H+L) HRP Conjugate	n/a	AB_11125142	170-6515	BIO-RAD	1:10000
Anti-mouse IgG, HRP-linked Antibody	n/a	AB_330924	7076	Cell Signaling Technology	1:5000

Supplemental Table 2. Panel of Western blot/ICC antibodies.

Target	F/R	Primer sequence 5'→3'
<i>UBC</i>	F	ATTTGGGTGCGAGTTCTTG
	R	TGCCTTGACATTCTCGATGGT
<i>CD279</i>	F	CGTGGCCTATCCACTCCTCA
	R	ATCCCTTGTCCCAGCCACTC
<i>CD274</i>	F	AAATGGAACCTGGCGAAAGC
	R	GATGAGCCCCCTCAGGCATTT
<i>CD273</i>	F	GAACCCAGGACCCATCCAAC
	R	TCCCAAGACCACAGGTTTCAG
<i>IL-1B</i>	F	CTCCGGGACTCACAGCAAAA
	R	TTTCAACACGCAGGACAGGT
<i>IL-6</i>	F	TGCAATAACCACCCCTGACC
	R	GTGCCATGCTACATTTGCC
<i>TGFB2</i>	F	GTTTGCACCATGCTTTGGCT
	R	ACAACCAACCCCAGAAAGCA
<i>AXL</i>	F	GACTATCTGCGCCAGGGAAA
	R	GGCCTTCAGTGTGTTCTCCA
<i>IDO1</i>	F	TGAACCCAAAAGCATTTTTCAGTGT
	R	CGTCAAAGCACTGAAAGACGCTG
<i>NLPR3</i>	F	GGCAACACTCTCGGAGACAA
	R	GGAAAGATCCCAGCAGCAGT
<i>IL-18</i>	F	GATAGCCAGCCTAGAGGTATGG
	R	CCTTGATGTTATCAGGAGGATTCA

Supplemental Table 3. List of qRT-PCR primers.

Characteristic	Values observed in mRCC patients (n=55)
Gender	
Male, n (%)	37 (67.3)
Female, n (%)	18 (32.7)
Mean age (IQR), years	63 (14.5)
Morphology	
clear cell, n (%)	39 (70.9)
non-clear cell, n (%)	19 (34.5)
sarcomatoid differentiation, n (%)	3 (5.5)
Fuhrman grade	
1, n (%)	5 (9.1)
2, n (%)	10 (18.2)
3, n (%)	10 (18.2)
4, n (%)	3 (5.5)
Unknown, n (%)	27 (49.1)
IMDC prognostic score	
0, n (%)	4 (7.3)
1, n (%)	15 (27.3)
2, n (%)	21 (38.2)
3, n (%)	8 (14.5)
4, n (%)	7 (12.7)
Metastases	
lungs, n (%)	29 (52.7)
bone, n (%)	26 (47.3)
liver, n (%)	10 (18.2)
brain, n (%)	5 (9.1)
ECOG performance score	
0, n (%)	8 (14.5)
1, n (%)	36 (65.5)
2, n (%)	10 (18.2)
3, n (%)	1 (1.8)

Supplemental Table 4. Characteristic of patients treated with cabozantinib in mRCC.